GleamWall
中文EN

ARWR ARROWHEAD PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 879407 · Fiscal year ends 09/30

Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.6%
TTM net income YoY-44,302.3%
TTM EPS YoY-51,000.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-156.9%
Net margin-160.6%
FCF margin-63.0%
EBITDA margin-151.4%

Returns

ROE-280.5%
ROA-46.4%
ROIC (approx.)-492.0%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets97.1%
Debt / equity0.00x
Current ratio4.14x
Interest coverage-7.55x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-29.0%
Payout ratio—
Capex / revenue2.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q4*2026-09-302026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-31
Income statement
Revenue$37.79M$75.25M$73.74M$264.03M$256.47M$27.77M$542.71M$2.50M
R&D expense$190.47M$198.22M$173.25M$177.20M$174.69M$162.37M$133.10M$137.00M
SG&A expense$67.16M$47.12M$41.74M$46.02M$37.68M$30.95M$28.41M$26.91M
Operating income-$436.63M-$170.09M-$141.26M$40.81M$44.11M-$165.55M$381.20M-$161.41M
Interest expense$22.80M$24.56M$23.85M$22.50M$21.69M$24.38M$21.64M$21.65M
Pretax income-$435.71M-$178.91M-$137.56M$28.27M$36.12M-$179.09M$369.62M-$175.12M
Income tax-$6.83M$11,000$7,000$29,000$20.00M-$437,000$1.75M$103,000
Net income-$428.00M-$194.28M-$132.73M$30.81M-$23.75M-$175.24M$370.44M-$173.09M
EBITDA-$430.03M-$163.89M-$135.36M$46.81M$50.11M-$159.75M$386.80M-$156.61M
EPS (basic)—-1.36-0.930.22—-1.262.78-1.39
EPS (diluted)—-1.36-0.930.22—-1.262.75-1.39
Weighted avg. shares (diluted)—143.38M142.42M140.71M—139.04M134.48M124.85M
Balance sheet
Cash & equivalents$62.73M$54.76M$188.52M$201.64M$226.55M$129.79M$185.71M$53.89M
Short-term investments$1.13B$1.55B$1.60B$714.97M$692.82M$770.58M$911.70M$499.05M
Receivables$9.93M$8.56M$15.69M$218.87M$6.82M$0$2.37M$2.50M
Inventory$9.07M———$0———
Current assets$1.29B$1.67B$1.84B$1.17B$950.64M$946.92M$1.14B$570.54M
PP&E, net$371.31M$373.30M$374.82M$378.58M$382.51M$381.05M$384.80M$387.07M
Intangibles$5.16M$5.59M$6.01M$6.44M$6.86M$7.29M$7.71M$8.14M
Total assets$1.74B$2.11B$2.27B$1.60B$1.39B$1.38B$1.57B$1.01B
Current liabilities$311.34M$283.35M$295.22M$347.43M$195.49M$194.53M$220.54M$93.76M
Total liabilities$1.69B$1.65B$1.67B$1.04B$881.88M$860.81M$889.27M$957.62M
Shareholders' equity$50.31M$465.53M$613.98M$568.42M$466.05M$522.31M$683.32M$52.59M
Shares outstanding141.29M141.13M140.57M137.39M135.70M138.14M138.06M125.57M
Cash flow statement
Operating cash flow-$192.40M-$177.47M$84.44M$13.48M$20.49M-$154.72M$460.05M-$146.27M
Capital expenditure$3.43M$3.85M$2.56M$2.15M$7.49M$2.36M$5.30M$7.52M
Free cash flow-$195.83M-$181.32M$81.88M$11.33M$13.00M-$157.08M$454.76M-$153.79M
Investing cash flow$203.86M$43.68M-$894.28M-$23.74M$72.62M$141.39M-$420.21M$76.91M
Financing cash flow-$3.70M-$449,000$795.72M-$14.75M$3.67M-$42.68M$92.38M$20.63M
Depreciation & amortization$6.60M$6.20M$5.90M$6.00M$6.00M$5.80M$5.60M$4.80M
Stock-based compensation$17.23M$14.97M$16.57M$19.37M$19.09M$11.99M$15.08M$15.21M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.